JACC:原发性心脏肿瘤的远期预后研究

2020-05-15 MedSci原创 MedSci原创

原发性心脏恶性肿瘤的临床资料仅限于小型单中心研究。本研究的目的是从多中心数据库中为原发性心脏恶性肿瘤的治疗提供详细的结果。

原发性心脏恶性肿瘤的临床资料仅限于小型单中心研究。本研究的目的是从多中心数据库中为原发性心脏恶性肿瘤的治疗提供详细的结果。

本研究纳入分析了100317名心脏肿瘤患者,其中826名(0.6%)为原发性心脏肿瘤患者,经过排除标准,最终纳入分析了747名原发性心脏肿瘤患者(平均年龄53岁,女性占47.5%)。大部分原发性肿瘤为原发性肉瘤(88.5%),且以血管肉瘤为主(40.4%)。有136名患者没有接受治疗,113名仅接受了化疗,20名仅接受了放疗。有442名患者接受了手术治疗,包括255名接受的是联合治疗(手术和放化疗)。对于仅接受手术治疗的患者,90天死亡率为29.4%,30天、1年和5年的整体生存率分别是81.2%, 45.3%和11.5%。手术组与非手术组相比,长期生存率明显提高(p<0.0001)。对于III期疾病,手术加化疗后生存率在统计学上有明显改善。

研究结果显示,原发性心脏恶性肿瘤是一种罕见的癌症,尽管有治疗方法,但长期存活率很低。接受手术治疗的患者和接受围手术期化疗的III期患者的生存率高于未接受手术治疗的患者。

原始出处:

Ibrahim S et al.Long-Term Outcomes of Primary Cardiac Malignancies.JACC.2020 may.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-09-13 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1984394, encodeId=e21f198439423, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Dec 31 21:10:55 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655273, encodeId=22b616552e3e0, content=<a href='/topic/show?id=956151660c2' target=_blank style='color:#2F92EE;'>#心脏肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51660, encryptionId=956151660c2, topicName=心脏肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e724711221, createdName=yeaweam, createdTime=Wed Apr 28 15:10:55 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846893, encodeId=f25d184689354, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Mar 06 15:10:55 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854770, encodeId=d0951854e707b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Sep 13 19:10:55 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326616, encodeId=4f7a1326616f7, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 17 00:10:55 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382839, encodeId=6d2838283990, content=很好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/2690090c15ff4d0181b6c45ca2ffd1e2/9f00b8c9ed6c460eb8ed3e3500194f3d.jpg, createdBy=10652049728, createdName=阿菡, createdTime=Fri May 15 09:39:51 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 阿菡

    很好的文章

    0

相关资讯

JACC:房隔瘤和分流大小对卵圆孔未闭患者卒中复发的影响

在卵圆孔未闭(PFO)的患者中,大分流或房间隔动脉瘤(ASA)的存在被认为是卒中复发的高危因素。本研究的目的旨在评估PFO的大小和ASA对卒中复发的影响。

NAT COMMUN:曲静/汤富酬/刘光慧合作揭示血管衰老的分子机制

至今为止,我们对衰老如何影响血管的细胞和分子成分,并导致心血管疾病的了解仍然有限。

JACC:evolocumab对动脉粥样硬化患者认知功能的影响

FOURIER临床试验结果显示添加到他汀类药物中的evolocumab不会影响患者的认知功能。本研究通过自我调查描述了整个FOURIER试验中患者报告的认知。

JACC:妊娠期高血压的发病率和远期预后研究

妊娠期高血压(HDP)与后期心血管疾病风险增加相关,HDP的发病率通常使用不可靠的诊断评分进行评估;而且通常是在每次怀孕时表达的,这可能低估了生育后有HDP病史的妇女的数量。这项研究试图确定HDP在每

BMJ:青少年时期体重指数对晚年心血管、糖尿病及肿瘤风险的影响

青少年时期体重指数较高或与较低的乳腺癌风险相关

JAHA:肠道菌群代谢物TMAO与心血管死亡风险相关

三甲胺N-氧化物(TMAO)可能具有血栓的特性。本研究的目的旨在评估TMAO四分位数与主要心血管不良事件(MACE)的相关性,以及TMAO对替卡格雷疗效的影响。